Androgen receptor, PARP signaling, and tumor microenvironment: the ‘perfect triad’ in prostate cancer?
Therapeutic Advances in Medical Oncology · 2024-01 · 16
DOI: 10.1177/17588359241258443 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 16.06.2024. Verfasst von Marianna Garofoli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, Foggia, It…. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aberrations in the homologous recombination repair (HRR) pathway in prostate cancer (PCa) provide a unique opportunity to develop therapeutic strategies that take advantage of the reduced tumor ability to repair DNA damage. Poly-ADP-ribose polymerase (PARP) inhibitors (PARPi) have been shown to prolong the survival of PCa patients with HRR defects, particularly in those with Breast Cancer type 1 susceptibility protein/Breast Cancer type 2 susceptibility protein alterations. To expand the benefit of PARPi to patients without detectable HRR alterations, multiple preclinical and clinical studies are addressing potential synergies between PARPi and androgen receptor signaling inhibitors, and these strategies are also being evaluated in combination with other drugs such as immune checkpoint inhibitors. However, the effectiveness of these combining therapies could be hindered by multiple mechanisms of resistance, including also the role played by the immunosuppressive tumor microenvironment. In this review, we summarize the use of PARPi in PCa and the potential synergies with different molecular pathways. However, numerous unanswered questions remain, including the identification of the patient population that could benefit most from PARPi, determining whether to use PARPi as monotherapy or in combination, and finding the optimal timing of PARPi, expanding the use of genomic tests, and optimizing combination therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, Foggia, Italy.
- Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.
- Unit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, Viale Pinto, 1, Foggia 71122, Italy.
ORCID-Profile: Marianna Garofoli, Brigida Anna Maiorano, Giuseppina Bruno, Guido Giordano, Matteo Landriscina, Vincenza Conteduca
Zitieren
APA
Garofoli, M., Maiorano, B. A., Bruno, G., Giordano, G., Di Tullio, P., Maselli, F. M., Landriscina, M., & Conteduca, V. (2024). Androgen receptor, PARP signaling, and tumor microenvironment: the ‘perfect triad’ in prostate cancer?. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241258443
Vancouver
Garofoli M, Maiorano BA, Bruno G, Giordano G, Di Tullio P, Maselli FM, et al. Androgen receptor, PARP signaling, and tumor microenvironment: the ‘perfect triad’ in prostate cancer?. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359241258443
BibTeX
@article{Garofoli2024,
author = {Garofoli, Marianna and Maiorano, Brigida Anna and Bruno, Giuseppina and Giordano, Guido and Di Tullio, Piergiorgio and Maselli, Felicia Maria and Landriscina, Matteo and Conteduca, Vincenza},
title = {Androgen receptor, PARP signaling, and tumor microenvironment: the ‘perfect triad’ in prostate cancer?},
journal = {Therapeutic Advances in Medical Oncology},
year = {2024},
volume = {16},
doi = {10.1177/17588359241258443}
}
EUVIMED